Relypsa Inc (NASDAQ:RLYP)‘s stock had its “outperform” rating restated by research analysts at Oppenheimer in a note issued to investors on Thursday, Analyst Ratings Network.com reports. They currently have a $55.00 price objective on the stock. Oppenheimer’s price target points to a potential upside of 180.33% from the stock’s current price.

A number of other research analysts also recently commented on the company. Zacks Investment Research reaffirmed a “sell” rating on shares of Relypsa in a report on Monday, January 18th. BTIG Research began coverage on Relypsa in a report on Tuesday, January 5th. They set a “buy” rating and a $45.00 target price on the stock. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Relypsa in a report on Sunday, January 3rd. Wedbush reaffirmed an “outperform” rating and set a $86.00 target price (up previously from $75.00) on shares of Relypsa in a report on Tuesday, December 22nd. Finally, HC Wainwright began coverage on Relypsa in a report on Thursday, December 17th. They set a “buy” rating and a $63.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $49.58.

Relypsa (NASDAQ:RLYP) traded up 0.05% during mid-day trading on Thursday, reaching $19.62. The company’s stock had a trading volume of 2,259,217 shares. Relypsa has a 52 week low of $10.26 and a 52 week high of $42.26. The firm’s market capitalization is $817.98 million. The firm’s 50 day moving average price is $25.17 and its 200 day moving average price is $24.00.

Relypsa (NASDAQ:RLYP) last released its earnings results on Wednesday, November 4th. The company reported ($1.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by $0.35. The business earned $6.50 million during the quarter, compared to the consensus estimate of $6.67 million. The firm’s revenue was up 6400.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.57) earnings per share. On average, analysts anticipate that Relypsa will post ($4.34) EPS for the current fiscal year.

Several institutional investors have recently modified their holdings of the stock. Janus Capital Management boosted its position in shares of Relypsa by 12.8% in the third quarter. Janus Capital Management now owns 4,085,220 shares of the company’s stock valued at $75,617,000 after buying an additional 464,854 shares during the period. Jennison Associates boosted its position in shares of Relypsa by 0.5% in the third quarter. Jennison Associates now owns 303,767 shares of the company’s stock valued at $5,623,000 after buying an additional 1,567 shares during the period. Finally, Simplex Trading boosted its position in shares of Relypsa by 548.5% in the fourth quarter. Simplex Trading now owns 33,826 shares of the company’s stock valued at $958,000 after buying an additional 28,610 shares during the period.

In related news, SVP Wilhelm Stahl sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 31st. The stock was sold at an average price of $28.53, for a total value of $570,600.00. Following the sale, the senior vice president now directly owns 14,853 shares in the company, valued at approximately $423,756.09. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO John A. Orwin sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, December 4th. The shares were sold at an average price of $25.00, for a total value of $1,000,000.00. Following the completion of the sale, the chief executive officer now owns 59,375 shares in the company, valued at $1,484,375. The disclosure for this sale can be found here.

Relypsa, Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. The Company’s lead product candidate, Patiromer for Oral Suspension (NASDAQ:RLYP) is for the treatment of hyperkalemia, a life-threatening condition defined as abnormally elevated levels of potassium in the blood. Its New Drug Application (NDA) for Patiromer FOS was accepted for filing by the United States Food and Drug Administration, or FDA. The Company’s NDA is supported by a clinical development program consisting of eight clinical trials: three Phase I trials, four Phase II trials and one two-part Phase III trial conducted under a Special Protocol Assessment, or SPA. The active ingredient is a cross-linked polymeric bead with a calcium containing counterion. The Company has the global royalty-free commercialization rights to Patiromer FOS.

12 Month Chart for NASDAQ:RLYP

Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).

Receive News & Ratings for Relypsa Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relypsa Inc and related companies with MarketBeat.com's FREE daily email newsletter.